Background

The initial evaluation of persons with hepatitis C virus (HCV) infection can include evaluation of a person newly diagnosed with HCV, or an individual previously diagnosed with HCV who is establishing clinical care for the management of HCV infection. The type of health professional who provides comprehensive HCV-related management can be a primary care clinician with competence in HCV clinical management or an HCV specialist. In the modern HCV treatment era that has safe, effective, and easy-to-use direct-acting antiviral (DAA) agents, the treatment of HCV has increasingly expanded into the primary care setting.[1] The capacity of primary care medical providers to treat HCV has also been enhanced by innovative strategies that use HCV treatment experts to support HCV clinical management by primary care medical providers, such as the use of group video conferencing as developed in the Extension for Community Healthcare Outcomes (ECHO) model.[2,3] In addition, the National Clinician Consultation Center for Hepatitis C Management provides free clinician-to-clinician advice either by phone (844-437-4636) Monday through Friday 9 a.m. to 8 p.m. EST or by submitting a case online at the Clinician Consultation Center website.
**General Approach to Initial Evaluation**

At the initial visit, it is very important to review the HCV test results and confirm the individual has chronic HCV infection (viremic) and not resolved HCV (negative or undetectable HCV viral load).[4] During the initial evaluation, the clinician should perform a thorough history and physical examination, focusing particularly on risk factors for acquiring HCV infection, presence of significant medical comorbidities, current or past substance use disorders, coinfection with other blood-borne viruses (e.g. HIV, hepatitis B virus), stigmata of chronic liver disease, clinical manifestations attributable to HCV infection, prior assessment of liver fibrosis, and any history of prior treatment.[5] Assessment of the stage of liver disease is a complex task and should be addressed in subsequent follow-up visits.
Key Aspects of Medical History

In addition to performing a standard and comprehensive history, the initial evaluation should assess for any ongoing risk of HCV transmission, ascertain for use of alcohol or any other substance use that may cause further liver toxicity, and identify any potential barriers to treatment.

Identifying Risk Factors for HCV Acquisition

Identifying how an individual likely acquired HCV is important for counseling on how to prevent transmitting HCV to others and how to prevent reinfection with HCV if cured with treatment. In the United States, the major risk factors for HCV acquisition are injection drug use, receipt of a blood transfusion or organ transplant prior to 1992, exposure to a sexual partner with HCV, occupational needlestick injury, nonsterile tattooing, and mother-to-child transmission. During the past decade there has been a surge in the number of reported new annual acute HCV infections that in large part is attributable to the opioid epidemic and associated injection-drug use. In addition, there has been an increase in reported cases of sexually transmitted HCV among men who have sex with men (MSM), particularly men with HIV. Some individuals may not disclose a possible risk factor for acquiring HCV at the initial visit—when this occurs the clinician should readdress the issue at a later point after they have hopefully established a good rapport with the person. The reluctance to disclose risk of HCV acquisition is particularly common in individuals who have a remote history of injection-drug use.

Alcohol History

Determining the presence of current and prior alcohol use is important since ongoing alcohol intake of even moderate amounts (50 g/day or more) in persons with HCV may accelerate progression of liver fibrosis. Obtaining an accurate alcohol history can be difficult in some persons with chronic alcohol use disorder. Several well-validated tools are recommended to screen for alcohol use disorder, including the CAGE Questionnaire, a 4-question screening tool (Figure 1), and the Alcohol Use Disorders Identification Test (AUDIT). The AUDIT-C is a 3-question modified version of the 10-question AUDIT screening instrument and is a more practical tool for screening in clinical settings than the AUDIT (Figure 2).

Injection Drug Use History

Injection-drug use remains an important risk factor for acquisition of HCV. For persons who report injection-drug use, it is important to assess whether the injection-drug use is active, and, if they are not actively injecting drugs, whether they are likely to use again in the future. Asking about injection-drug use may aid in determining the initial mode of HCV acquisition, which may inform further screening for coinfections, such as HIV and hepatitis B virus (HBV). Further, individuals with active injection-drug use should receive counseling on safe injection practices that prevent transmission of HCV to others, and should be offered referrals to harm reduction services and drug treatment programs. In the modern DAA era, ongoing active injection-drug use or use of opioid agonist therapy is not a contraindication to treatment for HCV. For persons who undergo successful HCV treatment, future injection-drug use may place them at risk of becoming reinfected with HCV.

Prior Staging of Liver Fibrosis

For individuals who have previously engaged in HCV-related clinical care, it is important to determine whether they have had prior evaluation and staging of liver fibrosis. Methods to assess liver fibrosis include serum-based Aspartate aminotransferase-to-Platelet Ratio Index (APRI), FibroTest, liver transient elastography, hepatic ultrasound, and liver biopsy. If a liver biopsy has been performed, it is important to document the sample size, fibrosis score, and fibrosis scoring system used in the report.
Complications of Liver Disease

At the initial evaluation, it is important to determine whether the person with HCV has a history of any liver-related complications, particularly those associated with advanced liver disease. Treatment of HCV in persons with compensated cirrhosis may be more complex than in persons without cirrhosis. In addition, identifying a person with decompensated cirrhosis (Child-Turcotte-Pugh class C) should prompt an immediate referral to a hepatologist. If a history or examination indicates cirrhosis, it is important to inquire about prior hospital admissions for ascites, hepatic encephalopathy, jaundice, or gastrointestinal bleeding. Further, any person with HCV and untreated hepatocellular carcinoma should have prompt referral to a hepatologist and liver cancer specialist.

HCV-Associated Extrahepatic Manifestations

Infection with HCV may be associated with a diverse array of extrahepatic manifestations, such as cryoglobulinemia, thyroid disease, arthralgias, neuropathy, nephropathy, glomerulonephritis, lichen planus, insulin resistance, and B-cell lymphomas.[28,29] These extrahepatic manifestations are addressed in detail in the topic review Extrahepatic Conditions Related to HCV Infection. As part of the initial evaluation, the clinician should inquire about any symptoms, such as arthralgia, paresthesia, myalgia, pruritus, skin rash, dry eyes, or dry mouth, that may indicate an extrahepatic complication.[30]

History of Prior Treatment for HCV

For individuals who have previously undergone unsuccessful treatment for HCV the clinician should determine the type, timing and duration of prior treatment, degree of adherence, adverse effects, and if possible, viral kinetics and outcome on treatment. Failure to achieve a sustained virologic response (SVR) occurs as a result of nonresponse or relapse. Nonresponders are patients who never cleared HCV from their serum during the course of treatment (Figure 3). Virologic relapse refers to persons who have virologic rebound after achieving an end-of-treatment response, with this usually occurring within the first 12 weeks after treatment completion (Figure 4). As delineated in the AASLD-IDSA HCV Guidance, determining the unsuccessful prior treatment regimen is essential to guide recommendations for future therapy.[31]

Presence of Medical Comorbidities

When evaluating an individual with HCV, the clinician should inquire about any secondary causes of liver disease, such as nonalcoholic fatty liver disease (NAFLD), alcoholic hepatitis, alpha-1 antitrypsin deficiency, hemochromatosis, or autoimmune hepatitis.[32,33,34,35,36,37,38] A past or current history of obesity is important to obtain since obesity is strongly associated with the development of NAFLD.[39] The presence of renal impairment may influence treatment regimen.

Presence of Significant Coinfections

Every person newly evaluated for HCV should be asked about a history of hepatitis A virus (HAV), HBV, and HIV. Coinfection with either HBV or HIV is known to accelerate the rate of hepatic fibrosis, and acute HAV in a person with HCV can lead to fulminant hepatic failure.[40,41,42] Persons with chronic HCV infection who are nonimmune to HAV and HBV, should receive immunization against HAV and HBV.

Psychiatric History

Individuals with chronic HCV infection have a higher prevalence of psychiatric illness when compared with the general population.[43,44,45] In the modern treatment era, psychiatric illness is not a contraindication to treatment, but it may create challenges with regard to linkage to care, HCV treatment adherence, and drug interactions between psychiatric medications and direct-acting antiviral medications.[46,47]
Key Aspects of Physical Examination

Physical Examination of a Person with HCV Infection

During the initial evaluation visit, the clinician should ideally perform a complete physical examination, including obtaining the individual’s height and weight to determine the body mass index (BMI). The calculation of an individual’s BMI is based on their weight (pounds) and height (inches) (BMI Calculator) (Figure 5). The National Heart, Lung, and Blood Institute has BMI Tables for interpreting the calculated BMI result. In addition, there are several liver-related physical findings that should be specifically sought that may identify the presence of indicators of advanced liver disease.

Physical Examination Findings in Patients with Cirrhosis

The following is a description of some key physical examination findings that should indicate the presence of cirrhosis.[48,49,50,51]

- **Ascites** (Figure 6): Ascites, which is defined as an abnormal accumulation of fluid in the abdominal cavity, is the most common complication of cirrhosis, with approximately 50% of patients with compensated cirrhosis developing ascites over a 10-year period. The presence of bulging flanks suggests the presence of ascites.[52] In order for the flank dullness to be appreciated on physical exam, at least 1,500 mL of fluid needs to be present. The shifting dullness test improves the diagnostic sensitivity of physical examination for detecting the presence of ascites.[52]

- **Distended Abdominal Veins and Caput Medusae** (Figure 7): If a person with cirrhosis develops portal hypertension, the increased pressure can cause swelling of the collateral venous channels, which may become evident as distended abdominal veins. The distended abdominal veins can radiate around the umbilicus, a finding referred to as caput medusae.[53,54] On general inspection, the cirrhosis-related abdominal vein swelling can appear similar to findings with obstructions of the inferior vena cava.

- **Gynecomastia** (Figure 8): The presence of true gynecomastia refers to enlargement of the male breast glandular tissue and should be distinguished from generalized breast enlargement from fat accumulation in the breast region (lipomastia), which may be associated with obesity.[55] Cirrhosis-related gynecomastia results from impaired hepatic degradation of estrogens, a problem enhanced in patients with excess alcohol consumption (because of the phytoestrogens in alcohol). The finding of gynecomastia is not specific to cirrhosis.[55,56]

- **Jaundice** (Figure 9): The term jaundice refers to a yellow discoloration of the skin or sclera that results from excess deposition of biliary pigments. The sclera and mucous membranes under the tongue are the most sensitive sites to detect jaundice.[57] Jaundice is usually detected only when the serum bilirubin level exceeds 2.5 mg/dL. In one study, 58% of clinicians were able to detect scleral icterus when the serum bilirubin was 2.5 mg/dL and 68% when the serum bilirubin was 3.1 mg/dL.[57] Among persons with cirrhosis, the finding of jaundice is often an indicator of advanced liver disease, and in persons with chronic liver disease it strongly suggests decompensated cirrhosis. Jaundice can result from non-hepatic causes, such as hemolytic anemia.

- **Palmar Erythema** (Figure 10): The finding of palmar erythema is suggested by the presence of intense erythema in the thenar and hypothenar eminence (base of the thumb and fifth finger) of the palm, with the central region of the palm spared.[58] Approximately 25% of persons with cirrhosis have palmar erythema. This finding is not specific to cirrhosis and can be seen in pregnant women, thyrotoxicosis, and rheumatoid arthritis.[50]

- **Splenomegaly**: To increase the likelihood of palpating the spleen, have the patient lay on their right side and flex their legs towards their body. The detection of splenomegaly on physical examination suggests cirrhosis and portal hypertension.[49]

- **Spider Nevi (Spider Angiomata)** (Figure 11): This finding results from dilated arterial blood vessels found just below the skin surface. The lesion is referred to as a spider nevus because of the
appearance of the central arteriole that has multiple thin-walled radiating blood vessels that resemble spider legs.[59] With direct compression on the central region of the lesion, the lesion will temporarily blanch, but with release of pressure the lesion fills back in from the center, radiating outward. Typically, more than three spider nevi is considered abnormal, but this finding is not specific to liver disease. In patients with cirrhosis, elevated levels of vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF), and substance P are thought to play a role in the development of spider angioma.[60]

- **Terry's Nails** (Figure 12): The initial finding of Terry's nails consists of a white-silver discoloration of the proximal nail bed, typically with a pink band on the distal portion of the nail bed; as this process progresses, the white discoloration can involve about 80% of the nail bed, with only a 0.5 to 3.0 mm pink band remaining on the distal nail plate.[61,62] This finding can be distinguished from onychomycosis, since Terry's nails involves the nail bed and has a pink-brown band, whereas onychomycosis involves the nail itself, without any pink distal band.

**Accuracy of Physical Examination for Detecting Cirrhosis**

Although cirrhosis is ultimately a histological diagnosis, several clinical signs and symptoms strongly suggest the presence of cirrhosis. In a meta-analysis of 86 studies, Udell and coworkers found that specific physical examination findings increase the likelihood a patient has cirrhosis: distended abdominal veins, encephalopathy, ascites, and spider nevi (all with a likelihood ratio [LR] greater than 4).[49] The LR of any clinical finding is the probability of that finding in patients with disease divided by the probability of the same finding in persons without disease.[63] Although Terry's nails and gynecomastia had high likelihood ratios, the confidence intervals were broad and thus harder to interpret their validity. The following is a list of the summary measures for the diagnostic accuracy of the physical examination for detecting cirrhosis, in decreasing order of positive likelihood ratio (LR) for the presence of cirrhosis:

- Terry's nails (LR = 16.0-22.0)
- Gynecomastia (LR = 5.8-35.0)
- Distended abdominal veins (LR = 11.0)
- Encephalopathy (LR = 10.0)
- Decreased body hair (LR = 9.0)
- Ascites (LR = 7.2)
- Facial telangiectasia (LR = 5.9-10.0)
- Testicular atrophy (LR = 5.8)
- Palmar erythema (LR = 5.0)
- Spider nevi (LR = 4.3)
- Jaundice (LR = 3.8)
- Splenomegaly (LR = 3.5)
- Firm liver (LR = 3.3)
- Peripheral edema (LR = 3.0)
Recommended Initial Laboratory Studies

Initial Laboratory Evaluation

A core set of baseline laboratory tests are indicated for all persons newly undergoing evaluation for HCV infection and for those reestablishing medical care for management of HCV.[5] The major goals of the initial laboratory evaluation are two-fold: (1) identify any abnormalities directly related to the HCV-related liver injury, such as thrombocytopenia, liver dysfunction, or inflammation, and (2) evaluate for any common extrahepatic manifestations of chronic HCV infection, such as thyroid disease, cardiovascular disease, or renal disease.[5,28] The following summarizes the key laboratory studies to obtain in the initial evaluation.

- **General Laboratory Evaluation**: Complete blood count (CBC), platelet count, serum creatinine, and thyroid function tests (TSH).
- **Hepatic Inflammation and Function**: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST), total and direct bilirubin, alkaline phosphatase, serum albumin, international normalized ratio (INR).
- **Assays to Detect Relevant Coinfections**: Hepatitis A antibody, hepatitis B surface antigen, hepatitis B core antibody, hepatitis B surface antibody, HIV antibody.
- **HCV RNA Level (“Viral Load”)**: It is important to assess a quantitative HCV RNA viral load to confirm that the patient indeed has chronic HCV infection, and also to establish a pretreatment baseline level. In the absence of treatment, it is not necessary to repeatedly assess the HCV RNA levels, as monitoring values over time does not provide useful prognostic information and does not determine who should receive treatment.
- **HCV Genotype**: There are six major distinct HCV genotypes, each with slightly different epidemiologic and clinical characteristics. In the United States, HCV genotype 1 is most common, accounting for 74% of cases. Historically, determining the HCV genotype has been recommended, but with the availability of several pangenotypic DAA regimens, obtaining the HCV genotype is no longer recommended on a routine basis. If, however, a regimen that is not pangenotypic is planned for HCV treatment, then an HCV genotype should be performed.
- **IL-28B Testing**: The single nucleotide polymorphism (SNP) at the IL-28B locus codes for interferon lambda and strongly correlates with interferon-based HCV treatment responses. This polymorphism also explains much of the observed racial and ethnic variation in response to HCV treatment with interferon-based therapy. Patients who are C/C homozygous typically have a greater chance of spontaneous clearance of HCV and the best treatment response to interferon-based therapies. In the current era of DAA therapy, performing IL-28B testing is not recommended as it has been shown to be less predictive of treatment outcome.
Immunizations for Persons with Chronic HCV

Hepatitis A Immunization

Persons with chronic HCV are more likely to have severe manifestations of acute HAV infection and thus hepatitis A vaccine is recommended for all persons without immunity to HAV.[40,64] The hepatitis A immunization can be accomplished via a two-dose, single hepatitis A antigen vaccine or as a 3-dose Hepatitis A/B combination vaccine (Figure 13).[64] Checking post-vaccination hepatitis A titers is not routinely recommended for most persons, primarily because of the very high response to hepatitis A vaccine.[64]

Hepatitis B Immunization

Similar to the recommendations for hepatitis A immunization, all persons with chronic HCV should receive HBV vaccine, unless they have immunity to HBV or are chronically infected with HBV.[65] Traditionally, the hepatitis B vaccine series consists of a three-dose series using recombinant HBV vaccine, but recently a 2-dose hepatitis B vaccine series that can be completed in 1 month has been FDA-approved and this new hepatitis B vaccine utilizes the CpG 1018 adjuvant; there is also a 3-dose series hepatitis A/B combination vaccine available (Figure 14).[66,67,68]

Pneumococcal Immunization

The Advisory Committee on Immunization Practices (ACIP) recommends that persons aged 19 through 64 with chronic liver disease receive one dose of the 23-valent polysaccharide pneumococcal vaccine (PPSV23).[69,70] At age 65, all adults, including those with liver disease, should receive one dose of pneumococcal conjugate vaccine (PCV13) and a dose of PPSV23, with the dose of PPSV23 given at least 1 year after the PCV13 and at least 5 years after any prior dose of PPSV23 they may have received.[69] Currently, there are no recommendations to give PCV13 specifically for chronic liver disease.[69]

Routine Adult Vaccines

Entry into care represents an opportunity to administer standard adult vaccinations, such as yearly influenza and a one-time Tetanus Diphtheria Acellular Pertussis (Tdap) or Tetanus Diphtheria (Td) booster every 10 years.
Screening for other Causes of Liver Disease

Overview of Screening for Other Causes of Liver Disease

In the course of a new evaluation of a person with chronic HCV, the clinician should make an effort to determine whether additional causes of liver disease are present, especially in cases with significant abnormalities on liver function testing. Other causes of liver disease may coexist with HCV infection, including both hereditary and acquired conditions (Figure 15).[71] Identifying additional causes of liver disease in persons with chronic HCV is important since the combination of diseases may result in accelerated fibrosis progression or ongoing fibrosis progression even after HCV eradication. An exhaustive screening laboratory work-up for all of these conditions would be expensive and low-yield for most patients; however, they may be relevant in special situations. Therefore, the clinician should be familiar with some of the most important nonviral causes of hepatic inflammation.

Alcoholic Liver Disease

Chronic excessive alcohol consumption is the most common cause of liver disease in the Western world and determining alcohol intake is important in persons with HCV infection.[72, 73] On a practical basis, differentiating liver injury caused by alcohol use from that due to chronic HCV infection can be difficult, but the finding of an AST/ALT ratio of greater than 2.0 suggests alcohol-related injury, although this pattern may also be seen in advanced cirrhosis of any cause.[74, 75] In addition, screening for alcohol intake as part of the medical history, as outlined above, may provide useful information on whether alcohol is a likely contributor to liver disease. Excessive alcohol use can cause acute alcoholic hepatitis, fatty liver (steatosis), and eventually cirrhosis.[72, 75, 76] In addition, alcohol use clearly accelerates HCV-associated fibrosis and hastens the onset of cirrhosis.[77, 78] Given that no consensus exists regarding a safe level of alcohol consumption for persons with chronic HCV infection, most experts recommend all persons with HCV infection abstain from alcohol.[79]

Nonalcoholic Fatty Liver Disease (NAFLD)

Globally, an epidemic in chronic liver disease caused by nonalcoholic fatty liver disease (NAFLD) has emerged due to changes in lifestyle and increasing prevalence of obesity.[80] In the United States, the prevalence of obesity is high and the NAFLD prevalence in adults is estimated at approximately 24%. [81] The AASLD defines NAFLD as (1) evidence of hepatic steatosis documented either by imaging or histologic findings on liver biopsy, and (2) lack of any secondary cause of hepatic fat accumulation, such as significant alcohol consumption, long-term use of a steatogenic medication, or monogenic hereditary disorders.[82] Common conditions that have an established association with NAFLD include obesity, dyslipidemia, type 2 diabetes mellitus, metabolic syndrome, and polycystic ovary syndrome.[82] The AASLD classifies NAFLD into two subcategories—nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) based on histologic findings: (1) NAFL is defined as 5% or more hepatic steatosis without evidence of hepatocellular injury and (2) NASH is defined as 5% or more hepatic steatosis with evidence of hepatocellular inflammation and injury.[35] The development of NASH can result in progression to cirrhosis, liver failure, and hepatocellular cancer.[80, 83] The diagnosis of NAFLD requires documented absence of ongoing or recent substantial alcohol ingestion.[35] Two radiographic tests—magnetic resonance imaging by spectroscopy or magnetic resonance imaging with proton hepatic assessments—appear promising as noninvasive methods to estimate the degree of hepatic steatosis, but liver biopsy remains the gold standard for determining the presence and severity of NAFLD.[35]

Alpha-1 Antitrypsin Deficiency

This rare condition is characterized by deficiency of the alpha-1 antitrypsin enzyme, resulting in overly active proteases in the body and concomitant lung and liver destruction (emphysema and cirrhosis).[84, 85] It has a genetic basis with complex inheritance and variable penetrance, but is most prevalent in Caucasians of...
Scandinavian descent. In the United States and Western Europe, the prevalence of alpha-1 antitrypsin deficiency is estimated between 1 in 2,000 and 1 in 5,000 population.\[85\] A serum alpha-1 antitrypsin level below 11 μmol/L (80 mg/dL) should prompt specific genetic testing for the most common alpha-1 antitrypsin deficiency alleles.\[38\]

**Hemochromatosis**

Hemochromatosis is defined as an excessive accumulation of iron in the liver; hemochromatosis may result from excessive blood transfusions, erythrocyte disorders, or as a hereditary condition that involves a defect in iron metabolism.\[71\] With hereditary hemochromatosis, the total amount of body iron accumulates over time, which is associated with increased hepatic iron that can eventually cause tissue injury and cirrhosis.\[86\] Type 1 hereditary hemochromatosis is the most common and best-studied hereditary hemochromatosis variant and is caused by mutations in the human factors engineering (HFE) gene.\[87\] Initial diagnostic laboratory studies that suggest a diagnosis of hemochromatosis include elevated serum iron, elevated serum ferritin concentration, and elevated transferrin saturation.\[86,87\] A definitive diagnosis of hemochromatosis requires either liver biopsy with determination of iron index, or a specific battery of genetic testing. For screening purposes, most expert guidelines, including those from the American College of Physicians (ACP) and the American Association for the Study of Liver Diseases (AASLD), recommend using the following cutoffs when screening for iron overload: transferrin saturation greater than 45% and a serum ferritin greater than 200 ng/mL (for men) and greater than 150 ng/mL (for women).\[88,89,90\]

**Autoimmune Hepatitis**

This relatively rare condition results from both genetic and host factors. The disorder is believed to result from the host losing tolerance to its own liver antigens, which leads to an immune response that includes activated immune cells, autoantibodies, interferons, and proinflammatory cytokines, which together cause hepatic inflammation.\[91,92\] Most experts classify autoimmune hepatitis as type 1 or type 2.\[34,92\] Autoimmune hepatitis-1 is more common than autoimmune hepatitis-2 and can affect children or adults, although it predominantly occurs in adults. Approximately 20% of persons with autoimmune hepatitis-1 will have an extrahepatic autoimmune disorder, such as autoimmune thyroid disease, arthritis, or inflammatory bowel disease.\[92\] Autoimmune hepatitis-2 most often affects children and extrahepatic autoimmune complications are common, including autoimmune thyroid disease, insulin-dependent diabetes mellitus, Addison's disease, and arthritis.\[92\] Clinical and laboratory characteristics with autoimmune hepatitis include itching, joint pain, hypergammaglobulinemia, and chronic elevations in aminotransferase levels. The diagnosis typically depends on positive autoantibody studies combined with compatible clinical and histologic features.\[93,94\] Autoantibodies commonly found in persons with autoimmune hepatitis include smooth muscle antibodies (SMA), antinuclear antibodies (ANA), antimitochondrial antibodies (AMA), liver-kidney microsomal antibodies (LKM), and soluble liver/liver-pancreas antibodies (SLA/LP).\[95\] In 2008, the International Autoimmune Hepatitis Group published revised simplified criteria for the diagnosis of autoimmune hepatitis.\[95\]
Summary Points

- After confirming chronic HCV infection, the clinician should perform a thorough history, focusing particularly on risk factors for infection, presence of psychiatric disease, significant medical comorbidities, and coinfection with other viruses.
- In the initial evaluation, the clinician should perform a thorough history and physical examination, with a focus on stigmata of chronic liver disease, and manifestations attributable to HCV infection.
- A complete baseline laboratory examination of the newly diagnosed patient includes tests of hepatocellular inflammation, hepatobiliary disease, hepatic function, assays to detect relevant coinfections, and a limited panel of viral-specific measures to assist in staging and counseling regarding treatment.
- In addition to routinely recommended adult immunizations, all persons with chronic HCV infection should be immunized against hepatitis A and B (unless they are immune or have active infection).
- Prior to discussing specific treatment of HCV infection, the clinician should perform a thorough clinical and laboratory evaluation for other causes and contributors of liver disease.
Citations


22. AASLD-IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. When and in whom to initiate HCV therapy. [AASLD-IDSA Hepatitis C Guidance] -


31. AASLD-IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy failed. [AASLD-IDSA Hepatitis C Guidance] -


[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -
   [PubMed Abstract] -

   [PubMed Abstract] -

69. Advisory Committee on Immunization Practices. Recommended Immunization Schedule for Adults Aged 19 Years or Older by Medical Conditions and Other Indications, United States, 2021 [ACIP] -

   [PubMed Abstract] -

   [PubMed Abstract] -

   [PubMed Abstract] -

   [PubMed Abstract] -

   [PubMed Abstract] -

   [PubMed Abstract] -

   [PubMed Abstract] -

   [PubMed Abstract] -

   [PubMed Abstract] -

79. AASLD-IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. HCV testing and linkage to care.
   [AASLD-IDSA Hepatitis C Guidance] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -

[PubMed Abstract] -


References


- Yee LJ, Weiss HL, Langner RG, Herrera J, Kaslow RA, van Leeuwen DJ. Risk factors for acquisition of...
[PubMed Abstract] -
**Figures**

**Figure 1 CAGE Questionnaire for Detecting Alcoholism**

The CAGE Questionnaire is a simple 4-question screening tool. The acronym CAGE is derived from the question evaluation of Cutting down, Annoyance by criticism, Guilty feeling, and Eye-openers.

Figure 2 AUDIT-C Questionnaire for Detecting Alcoholism

The AUDIT-C is a 3-item screening questionnaire to help identify individuals who have alcohol use disorders (alcohol abuse or dependence). The AUDIT-C is a truncated version of the 10-question AUDIT screen.

Figure 3 Hepatitis C Treatment Nonresponse

Treatment nonresponders with hepatitis C therapy are those who have failed to achieve an undetectable HCV RNA level after a course of therapy (in this example showing response with 12 weeks of therapy).

Illustration: David H. Spach, MD
Figure 4 Hepatitis C Treatment Relapser

Patients treated for hepatitis C with relapse have an undetectable HCV RNA at the end of treatment, with rebound detectable HCV RNA after completion of therapy.
Figure 5 Body Mass Index (BMI) Formula

Body Mass Index (BMI) represents a number calculated based on a person's weight and height and it provides a good rough estimate of a person's body fat. The BMI may overestimate body fat in athletes and underestimate body fat in older persons, or individuals who have lost significant muscle.

Source: National Heart Lung and Blood Institute
Figure 6 Ascites

The presence of bulging flanks suggests a possible diagnosis of ascites; this should be confirmed with a shifting dullness test.

Illustration: Illustration by Jared Travnicek, Cognition Studio
Figure 7 Caput Medusa

Caput medusa results from portal hypertension and is manifested as distended abdominal veins radiating around the umbilicus.

Illustration: Illustration by Jared Travnicek, Cognition Studio
Figure 8 Gynecomastia

In men with cirrhosis, benign enlargement of the breasts may occur and manifest as gynecomastia.

Illustration: Illustration by Jared Travnicek, Cognition Studio
**Figure 9 Jaundice**

This illustration shows yellow discoloration of the sclera that results from excess deposition of biliary pigments.

Illustration: Illustration by Jared Travnicek, Cognition Studio
**Figure 10 Palmar Erythema**

With palmar erythema, the redness is most prominent in the thenar and hypothenar eminence, with sparing of the central region of the palm.

Illustration: Illustration by Jared Travnicek, Cognition Studio
Figure 11 Spider Angiomata

Spider angiomata are enlarged cutaneous blood vessels that resemble the appearance of a spider. Compression of the central aspect of the lesions causes the entire lesion to blanch; with release of compression, the blood quickly refills and the red color reappears.

Illustration: Illustration by Jared Travnicek, Cognition Studio
Figure 12 Terry’s Nails

Note the white-silver discoloration of the proximal nail bed and the pink band on the distal portion of the nail bed.

Illustration: Illustration by Jared Travnicek, Cognition Studio
**Figure 13 Hepatitis A Vaccine Dosages and Schedules for Adults**

Hepatitis A immunization includes an option of two types of hepatitis A vaccines, as well as a combined hepatitis A and B vaccine.
Figure 14 Hepatitis B Vaccine Dosages and Schedules for Adults

Hepatitis B immunization includes an option of three types of hepatitis B vaccines, as well as a combined hepatitis A and B vaccine.
**Figure 15 Potential Secondary Causes of Liver Disease in HCV-Infected Patients**

Abbreviations: AST=aspartate aminotransferase; ALT=alanine aminotransferase; ANA=antinuclear antibody; SMA=smooth muscle antibodies; anti-LKM1=anti-liver/kidney microsome type 1; SPEP=serum protein electrophoresis